Sequence variability of the outer surface protein (Osp) A among Borrelia burgdorferi sl species suggests that a monovalent OspA vaccine may not protect against the various Borrelia present in Eurasia. Here, we confirmed that a monovalent recombinant OspA (rOspA) vaccine does not protect mice against Ixodes ricinus mediated infection with B. burgdorferi ss, Borrelia garinii and Borrelia afzelii. However, when mice were vaccinated with a cocktail of various rOspA from these three species, they were protected, and all challenge ticks that fed on them were cleared of their spirochetes. These results showed that a multiple OspA antigens vaccine, compatible with human use, was very efficient at protecting mice against B. burgdorferi ss, B. garinii, and B. afzelii.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0264-410x(97)00066-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development, Optimization, and Validation of a Quantitative PCR Assay for Detection in Tick, Wildlife, and Human Samples.
Pathogens
November 2024
Department of Chemistry and Biochemistry, Université de Moncton, Moncton, NB E1A 3E9, Canada.
Tick-borne pathogens are growing in importance for human and veterinary research worldwide. We developed, optimized, and validated a reliable quantitative PCR (qPCR; real-time PCR) assay to assess Borrelia burgdorferi infection by targeting two B. burgdorferi genes, and .
View Article and Find Full Text PDFA single immunization of -infected mice with Vanguard crLyme elicits robust antibody responses to diverse strains and variants of outer surface protein C.
Infect Immun
November 2024
Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA.
Lyme disease, caused by and related species is a growing health threat to companion animals across North America and Europe. Vaccination is an important preventive tool used widely in dogs living in, or near, endemic regions. In this report, we assessed anti-outer surface protein (Osp) A and anti-OspC antibody responses in -infected and -naïve mice (C3H/HeN) after immunization with a murine-optimized single dose of the Lyme disease subunit vaccine, Vanguard crLyme.
View Article and Find Full Text PDFDevelopment of novel multi-protein chimeric immunogens that protect against infection with the Lyme disease agent, .
mBio
October 2024
Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, Virginia, USA.
Lyme disease is the most common tick-borne disease in North America. A vaccine for use in humans is not available. Here, we detail the development of two chimeric vaccine antigens, BAF and Chv2M.
View Article and Find Full Text PDFAssociation of Borrelia burgdorferi with nuchal bursitis and elevated outer surface protein A-specific serum antibodies in horses of the northeastern United States.
J Am Vet Med Assoc
November 2024
2Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY.
Article Synopsis
- The study aimed to assess how often Borrelia burgdorferi is found in equine nuchal bursitis cases and examine the link between elevated anti-OspA antibodies in horse serum and the presence of the bacteria in bursa or synovial fluid.
- A total of 45 horses' medical records were analyzed, including 19 with confirmed B burgdorferi infection and 15 healthy controls, with histological comparisons made between cases with and without bacterial detection.
- Results showed significantly higher OspA antibody levels in infected horses, but histopathological changes were similar regardless of bacterial presence, suggesting a previously underestimated role of B burgdorferi in equine nuchal bursitis.
Vaccination to Prevent Lyme Disease: A Movement Towards Anti-Tick Approaches.
J Infect Dis
August 2024
Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Lyme disease is caused by the spirochete, Borrelia burgdorferi, which is transmitted by Ixodes spp ticks. The rise in Lyme disease cases since its discovery in the 1970s has reinforced the need for a vaccine. A vaccine based on B burgdorferi outer surface protein A (OspA) was approved by the Food and Drug Administration (FDA) several decades ago, but was pulled from the market a few years later, reportedly due to poor sales, despite multiple organizations concluding that it was safe and effective.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!